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Abstract 
Objective: Hypovitaminosis D has been associated with respectively major depressive 
disorder, schizophrenia (SZ) and cognitive disorders in the general population, and with 
positive and negative symptoms and metabolic syndrome in schizophrenia. The objectives 
were (i) to determine the prevalence of hypovitaminosis D and associated factors (with a 
focus on depression and cognition) in a national non-selected multicentric sample of 
community-dwelling SZ subjects (ii) to determine the rate of SZ patients being administered 
vitamin D supplementation and associated factors. 
Methods: A comprehensive 2 daylong clinical and neuropsychological battery was 
administered in 140 SZ subjects included between 2015 and 2017 in the national 
FondaMental Expert Center (FACE-SZ) Cohort. Hypovitaminosis D was defined by blood 
vitamin D level <25nM. Depressive symptoms were assessed by the Positive and Negative 
Syndrome Scale depressive subscore and current anxiety disorder by the Structured Clinical 
Interview for Mental Disorders. 
Results: Hypovitaminosis D has been found in 21.4% of the subjects and none of them had 
received vitamin D supplementation in the previous 12 months. In multivariate analysis, 
hypovitaminosis D has been significantly associated with respectively higher depressive 
symptoms (aOR=1.18 [1.03-1.35], p=0.02) and current anxiety disorder (aOR=6.18 [2.15-
17.75], p=0.001), independently of age and gender. No association of hypovitaminosis D with 
respectively positive and negative symptoms, cognitive scores or other biological variables 
has been found (all p>0.05), however, a trend toward significance has been found for 
metabolic syndrome (p=0.06). Vitamin D supplementation has been administered during the 
previous 12 months in only 8.5% of the subjects but was associated with lower depressive 
symptoms (aOR=0.67 [0.46-0.98], p=0.04) and lower rate of current anxiety disorder 
(aOR=0.06 [0.01-0.66], p=0.02) compared to patients with hypovitaminosis D. 
 
Conclusion: Hypovitaminosis D is frequent and associated with depressive symptoms and 
anxiety disorders in schizophrenia. Vitamin D supplementation is associated with lower 
depressive and anxiety symptoms, however patients with hypovitaminosis D remain 
insufficiently treated.  
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Introduction 
 
Treating comorbid major depressive disorder (MDD) and anxiety disorders in SZ is 
clinically important due to the high prevalence of depression and suicidality in SZ and to its 
impact on functioning and quality of life (Andrianarisoa et al., 2017; Harvey, 2011). 
Hypovitaminosis D has been extensively associated with MDD in general population (for 
meta-analysis see (Ju et al., 2013) and for review see (Lerner et al., 2018)) and supplementing 
subjects with MDD has been found to improve depressive symptoms in another recent meta-
analysis (Schefft et al., 2017). Patients with SZ are at higher risk of hypovitaminosis D 
(Belvederi Murri et al., 2013) and this association has been replicated in first episode 
psychosis in another recent meta-analysis (Firth et al., 2017) (for review see (Adamson et al., 
2017)). Vitamin D deficiency may play a role in mediating hippocampal volume deficits, 
possibly through neurotrophic, neuroimmunomodulatory and glutamatergic effects 
(Shivakumar et al., 2015). A study has found high levels of hypovitaminosis in a monocentric 
sample of SZ inpatients in the south of France (Belzeaux et al., 2015) but no data is available 
to date in a national non-selected sample of community-dwelling SZ subjects. Studies 
exploring the association of vitamin D deficiency with psychotic symptomatology have 
yielded inconsistent findings (Akinlade et al., 2017; Cieslak et al., 2014; Nerhus et al., 2016; 
Yüksel et al., 2014). The association of vitamin D deficiency and depression in schizophrenia 
has been explored in only one study with positive results (Nerhus et al., 2016), and no study 
has explored the association between hypovitaminosis D and anxiety disorders in SZ subjects 
to date. Preliminary findings have suggested that vitamin D supplementation may improve 
cognition in schizophrenia (Krivoy et al., 2017), however the association of hypovitaminosis 
D with cognitive impairment has not been explored to date. Vitamin D insufficiency has been 
associated with metabolic syndrome in psychotic disorders (Yoo et al., 2018), with insulin 
resistance (Garbossa and Folli, 2017), with thyroid dysfunction (Kim, 2017; Wang et al., 
2018) and high vitamin D blood levels have been suggested to reduce peripheral low-grade 
inflammation (Zhu et al., 2015). There is a current debate on the association between alcohol 
use disorder and vitamin D deficiency (Tardelli et al., 2017). 
The objective were (i) to determine the prevalence of hypovitaminosis D and 
associated factors in a non-selected multicentric sample of community-dwelling SZ subjects 
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(ii) to determine the rate of vitamin D supplementation, its effectiveness in correcting vitamin 
D blood levels and the associated factors. Our hypotheses were that hypovitaminosis D was 
associated with higher depressive and anxiety disorders, higher cognitive impairment and 
higher biological disturbances. 
 
Population and methods 
 
Study design 
The FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) 
cohort is based on a French national network of 10 Schizophrenia Expert Centers (Bordeaux, 
Clermont-Ferrand, Colombes, Créteil, Grenoble, Lyon, Marseille, Montpellier, Strasbourg, 
Versailles), set up by a scientific cooperation foundation in France, the FondaMental 
Foundation (www.fondation-fondamental.org) and pioneered by the French Ministry of 
Research in order to create a platform that links thorough and systematic assessment to 
research (Schürhoff et al., 2015).  
 
Study population 
Consecutive clinically stable patients (defined by no hospitalization and no treatment 
changes during the 8 weeks before evaluation) with a DSM-IV-TR diagnosis of schizophrenia 
or schizoaffective disorder were consecutively included in the study. Diagnosis was 
confirmed by two trained psychiatrists of the Schizophrenia Expert Centres network. All 
subjects were referred by their general practitioner or psychiatrist who subsequently received 
a detailed evaluation report with suggestions for personalized interventions.  
Data collected 
Patients were interviewed by members of the specialized multidisciplinary team of the 
Expert Center. Diagnoses interviews were carried out by two independent psychiatrists 
according to the Structured Clinical Interview for Mental Disorders (SCID 1.0).  
All clinicians were blinded of the vitamin D status of the patient at the time of 
evaluation, and all technicians carrying out laboratory measurements were blinded of the 
diagnosis and evaluation. Information about age at illness onset, duration of untreated 
psychosis and illness duration was recorded. Current daily tobacco smoking was self-reported. 
Ongoing psychotropic treatment was recorded as well as other medication. Current alcohol 
and cannabis disorders were defined according to the Structured Clinical Interview for Mental 
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Disorders (SCID 1.0). The antipsychotic treatments were classified according to their 
Anatomical-Therapeutic-Clinical ATC class. First-generation antipsychotics (FGA) were 
defined by ATC class N05AA to AC (phenothiazines), NO5AD (butyrophenones), NO5AF 
(thioxanthenes). Second-generation antipsychotics (SGA) were defined by ATC class N05AH 
(diazepines, oxazepines, thiazepines and oxepines) and NO5AL (benzamides).  
The National Adult Reading Test (Nelson and O’Connell, 1978) provides an estimate 
of premorbid intellectual ability. French version of the NART was used in our analysis 
(Mackinnon and Mulligan, 2005). Wechsler Adult Intelligence Scale – 4th Edition (Wechsler, 
2008) provides a measure of general intellectual function in older adolescents and adults. 
Seven subtest short form (Ryan and Ward, 1999) was used to estimate the Full Scale IQ 
(FSIQ). Trail Making Test (Reitan, 1958) reflects the control of attention, visual exploration, 
speed and mental flexibility. The subject is asked to connect, by making pencil lines, 
encircled numbers randomly arranged on a page in proper order (Part A) and encircled 
numbers and letters in alternating order (Part B). A French version of the normative data was 
used (Godefroy, 2008). California Verbal Learning Test (Delis et al., 2000) is designed to 
measure verbal learning and memory using a multiple-trial list-learning task. The examiner 
reads the word list and records the patient’s oral responses verbatim in the order in which they 
are given. Learning efficiency, strategies, interference management and learning bias are 
measured. A French version of the task was used in this study (Poitrenaud et al., 2007). Doors 
test (Baddeley et al., 1994) is a visual recognition memory test in which participants view 
photographs of 12 doors for 3 seconds each. Immediately thereafter, participants are presented 
with 12 arrays of four doors each, and are asked to identify the door from the previous list. In 
the second part new photographs of doors are displayed, but the recognition stimuli are rather 
similar to the key list. The Continuous Performance Test – Identical Pairs (CPT-IP) is a 
computerised measure of sustained, focused attention or vigilance. This version is a part of 
MCCB-Matrics Consensus Cognitive Battery and involves monitoring a series of multiple 
digits and responding with a button press each time that two stimuli in a row are identical 
(Nuechterlein et al., 2008) 
Vitamin D measurement  
Seric 25-hydroxy-vitaminD3 (25(OH)VD3) was quantified in the hospital Laboratories using 
a commercial radioimmuno-assay (Diasorin,Stillwater,MN, USA). Hypovitaminosis D 
severity was defined in 2 classes according to the French National Nutrition Health Study 
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2006–2007: severe to moderate (<25 nM) vs mild or no hypovitaminosis D (≥25nM)(Unité de 
surveillance et d’épidémiologie nutritionnelle, 2007). 
 
Other biological measurements 
Routine blood exam has been systematically performed and triglycerides, LDL, HDL and 
total cholesterol as well as glucose (with fasting for at least 10h), uric acid, prolactinemia, 
highly-sensitive C-reactive Protein (CRP) and ultrasensitive TSH (TSHus) have been 
measured.  
Metabolic syndrome (MetS) definition 
Sitting blood pressure (BP) and anthropometrical measurements were recorded. Two BP 
measurements were made 30 seconds apart in the right arm after the participant had sat and 
rested for at least 5 minutes. A third BP measurement was made only when the first two BP 
readings differed by more than 10 mm Hg. The average of the 2 closest readings was used in 
the analysis. Waist circumference was measured midway between the lowest rib and the iliac 
crest with the subjects standing. This was performed with a tape equipped with a spring-
loaded mechanism to standardize tape tension during measurement. Body mass index (BMI) 
was calculated as weight in kilograms divided by the square of the height in meters. 
Overnight fasting blood was collected for metabolic profiles analysis. Fasting levels of serum 
triglyceride (TG) and fasting plasma glucose were measured by an automated system, and 
serum high-density lipoprotein cholesterol (HDL-C) level was measured by electrophoresis. 
Metabolic syndrome was defined according to the modified criteria of the International 
Diabetes Federation (IDF) (Alberti et al., 2006), which requires the presence of three or more 
of the following five criteria: high waist circumference (>94 cm for men and >80 cm for 
women), hypertriglyceridemia (≥1.7 mM or on lipid lowering medication), low HDL 
cholesterol level (<1.03 mM in men and < 1.29 mM in women), high blood pressure (≥ 
130/85 mmHg or on antihypertensive medication), high fasting glucose concentration (≥ 5.6 
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mM or on glucose-lowering medication). High sensitivity CRP (hs-CRP) was measured with 
an assay using nephelometry (Dade Behring). Abnormal CRP level was defined as >3 mg/L 
according to the (“The Emerging Risk Factors Collaboration”; 2010). Patients with hs-CRP 
levels >30 mg/L, which corresponds to an acute inflammation, were not included in the 
analyses (“The Emerging Risk Factors Collaboration”; 2010). 
 
Ethical concerns 
The study was carried out in accordance with ethical principles for medical research 
involving humans (WMA, Declaration of Helsinki). The assessment protocol was approved 
by the relevant ethical review board (CPP-Ile de France IX, January 18th, 2010). All data 
were collected anonymously. As this study include data coming from regular care 
assessments, a non-opposition form was signed by all participants. 
 
Statistical analysis 
Socio-demographics, clinical characteristics, cognitive scores, addictive behavior, 
treatments and biological variables are presented using measures of means and dispersion 
(standard deviation) for continuous data and frequency distribution for categorical variables. 
The data were examined for normal distribution with the Shapiro-Wilk test and for 
homogeneity of variance with the Levene test. Comparisons between (i) individuals with or 
without hypovitaminosis D (table 1) and supplemented vs. non-supplemented individuals 
(table 2), regarding all above-mentioned characteristics were performed using the chi-square 
test for categorical variables. Continuous variables were analyzed with Student t-tests for 
normally distributed data and in case of normality violation, additional Mann-Whitney tests 
were performed to confirm the result.  
Multiple logistic regressions were then performed to confirm the association between 
(i) hypovitaminosis D and respectively current anxiety disorder and depressive symptoms, 
after adjusting for age and gender (table 1) and (ii) vitamin D supplementation and 
respectively current anxiety disorders and depressive symptoms, after adjusting for age, 
gender and illness duration (table 2). Adjustment variables were selected based on their 
clinical interest (age, gender and illness duration) and on threshold P-value ≤0.05 as 
calculated from the univariate analyses statistical (none of the variables). The association of 
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vitamin D supplementation with cognitive scores has not been carried out because of 
statistical power lack (N=18). The final models included odds ratios and 95 % confidence 
intervals. This study was a confirmatory analysis. No correction for multiple testing has 
therefore been carried out, which is consistent with recommendations (Bender and Lange, 
2001). Analyses were conducted using SAS (release 9.3; SAS Statistical Institute, Cary, NC). 
All statistical tests were two-tailed, with α level set at 0.05. 
 
Results: Overall, 140 patients have been consecutively recruited. Hypovitaminosis D has been 
found in 21.4% of the subjects and none of them had received vitamin D supplementation in 
the previous 12 months. In multivariate analysis, hypovitaminosis D has been significantly 
associated with respectively higher depressive symptoms (aOR=1.18 [1.03-1.35], p=0.02) and 
current anxiety disorder (aOR=6.18 [2.15-17.75], p=0.001), independently of age and gender. 
No association of hypovitaminosis D with respectively daylight sun exposure, positive and 
negative symptoms, cognitive scores or other biological variables has been found (all p>0.05), 
however, a trend toward significance has been found for metabolic syndrome (p=0.06). 
Overall, 8.5% of the patients had been administered Vitamin D supplementation in the 12 
previous months, none of them had hypovitaminosis D. Vitamin D supplementation has been 
associated with lower depressive symptoms (PANSS depressive subscore) (aOR=0.67 [0.46-
0.98], p=0.04) and lower rates of current anxiety disorder (aOR=0.06 [0.01-0.66], p=0.02). 
 
Discussion 
 
Altogether, the present findings may be summarized as follows: in a national sample 
of community-dwelling stabilized SZ subjects mean aged 33 years, 21.4% were found with 
hypovitaminosis D. Hypovitaminosis D has been significantly associated with anxiety and 
depressive symptoms after adjustment for confounding factors, and vitamin D 
supplementation has been associated with lower depressive symptoms and lower rates of 
comorbid anxiety disorders. No association of hypovitaminosis D or vitamin D 
supplementation with other biological variables or addictive behavior has been found. 
We found a prevalence of hypovitaminosis D of 21.4%, which is lower than the rate of 
34% found in 202 SZ Dutch outpatients (Boerman et al., 2016). In a recent French study, a 
comparable rate of 34% was found for hypovitaminosis D in the French general population 
(Souberbielle et al., 2016), which suggests that hypovitaminosis D may be lower in SZ 
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patients than in general population. However, it should be mentioned that the present sample 
was younger (mean aged 32 years) than the general French population (mean aged 40), which 
may explain these discrepancies. The life expentancy of SZ subjects is 10 years lower than the 
general population and hypovitaminosis D is usually associated with older age (Custodero et 
al., 2018). A previous study has suggested that sun exposure was not sufficient to increase 
vitamin D blood levels (Bogers et al., 2016), which is consistent with the present results 
suggesting no association between number of hours outside per day and hypovitaminosis D. 
No information on vitamin D supplementation in the previous year was reported in Boerman 
et al. study (Boerman et al., 2016). These discrepancies may be due to differences in diet and 
complementary agent consumption that should be evaluated in further studies.  
The major finding of the present study is the association of hypovitaminosis D with 
respectively depressive symptoms but also current anxiety disorder (with a stronger 
association). The association with depressive symptoms has confirmed previous preliminary 
results (Nerhus et al., 2016). The association with anxiety disorders has been explored for the 
first time in the present study. This is probably due to the fact that no specific anxiety scale 
has been validated for schizophrenia to date. Future studies exploring the associations 
between hypovitaminosis D and clinical features in schizophrenia should therefore include 
specific anxiety measurements. Moreover, vitamin D supplementation has also been shown 
for the first time to be associated with lower depressive symptoms and lower rates of anxiety 
disorders in SZ subjects. Due to the low rate of patients supplemented with vitamin D (8.5%), 
larger samples are needed to replicate these findings. Due to the cross-sectional retrospective 
design, no causal association may be drawn from the present findings and further clinical 
trials are also needed to determine if vitamin D supplementation in patients with 
hypovitaminosis D may definitely improve depression and anxiety. Treating depression in 
schizophrenia remain a challenge in the current state of the art (Guillaume Fond et al., 2018), 
and vitamin D may be suggested as a low-cost and high benefit/risk ratio add-on therapy in 
SZ patients with depressive and anxiety symptoms.  
No association between positive and negative symptoms and hypovitaminosis D has 
been found in the present study, contrary to previous findings (Doğan Bulut et al., 2016; 
Graham et al., 2015). The discrepancy with Doğan Bulut et al. study may be due to the use of 
different scales (PANSS vs. Scale for the Assessment of Negative Symptoms SANS and 
Scale for the Assessment of Positive Symptoms SAPS) and discrepancies in antipsychotic 
treatments. The present sample was larger than other studies (N=140 vs. respectively N=80 
and N=20) (Doğan Bulut et al., 2016; Graham et al., 2015). Another explanation may be that 
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depressive symptoms may be strongly associated with negative symptoms (Fond G., et al., 
2018) and depressive symptoms have not been explored in the previous studies except one 
(Nerhus et al., 2016). No association of current illness severity (PANSS total score) or 
psychotropic drugs with hypovitaminosis D has been found in present work, which is 
consistent with some previous findings (Akinlade et al., 2017; Itzhaky et al., 2012). 
Altogether, these inconsistent results suggest the need for larger studies and for a quantitative 
meta-analysis.  
Contrary to what could have been expected, vitamin D has not been associated with 
metabolic syndrome, insulin resistance (proxy by fasting blood glucose), chronic low-grade 
inflammation (hs-CRP blood level) and oxidative stress (proxy by uricemia). The association 
with metabolic syndrome was near significance (p=0.06). This association has been 
extensively validated in non-SZ populations (Archontogeorgis et al., 2018; Barbalho et al., 
2018; Zhu and Heil, 2018), which may suggest a power lack in the present study that would 
be consistent with the results of Yoo et al. (Yoo et al., 2018). No association between vitamin 
D blood level and hs-CRP blood level has been found, while extensive works have shown the 
impact of vitamin D on peripheral inflammation (Garbossa and Folli, 2017). In the present 
study, only hs-CRP has been explored as an inflammatory marker, future studies should 
explore other inflammatory markers like cytokines IL1ß, IL6 and TNF α.  
Limits and future directions. These results should be replicated in larger samples and 
confirmed in longitudinal studies. Lifestyle habits should also been explored. The dose and 
duration of vitamin D supplementation have not been reported.  
The screening for depression and anxiety in SZ is rarely carried out. One explanation 
is the debate of the existence of major depression and anxiety disorders as comorbidities of 
schizophrenia (Guillaume Fond et al., 2018). Some authors suggest that anxiety and 
depressive symptoms are part of psychotic symptomatology (as measured by the PANSS 
depressive factor that includes anxiety and depressive symptoms) (Wallwork et al., 2012). 
However, major depression has been shown to be associated with lower quality of life 
independently of negative symptoms (Andrianarisoa et al., 2017). The other reason may be 
the perception of lack of effectiveness of antidepressants in SZ subjects, while a recent study 
has shown that antidepressants were associated with lower depressive symptoms in SZ 
subjects (Guillaume Fond et al., 2018). Some depressive symptoms are also associated with 
insight into illness and therefore not necessarily treated (Roux et al., 2018). Anxiety and 
depression may also be increased by addictions and sedentary lifestyle (Fond et al., 2013a; 
Leventhal et al., 2008). Future studies should include qualitative interviews to understand the 
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barriers to anxiety and depression assessment and treatment in SZ subjects. There is no 
reliable specific scale to measure anxiety in schizophrenia to date. 
Another barrier is that vitamin D may be identified as a complementary agent by 
psychiatrist, despite its medical prescription. Psychiatrists may therefore be doubtful on its 
efficacy, as vitamin D as an extremely good tolerance. Moreover, vitamin D may still not be 
identified an agent with psychotropic effects, despite the existence of vitamin D receptors in 
the brain and the efficacy on peripheral inflammation (G. Fond et al., 2018). Vitamin D has 
been recently shown to maintain extracellular fluid serotonin concentrations in the brain, 
thereby offering an explanation for how vitamin D could influence the trajectory and 
development of neuropsychiatric disorders (G. Fond et al., 2018). 
Strengths. The 2 daylong-standardized evaluation including comprehensive cognitive 
battery, the national multicentric recruitment and the multiple confounding factors taken into 
account in analyses may be mentioned in the strengths of the present work.  
 
 
Conclusion 
The present findings suggest that hypovitaminosis D is frequent and associated with 
anxiety disorders and depressive symptoms in SZ subjects. As these comorbidities are under 
diagnosed and under treated, these results may open the path to a new precision medicine 
strategy in the treatment of anxiety and depression in schizophrenia.  Future studies should 
confirm that vitamin D supplementation may be effective in alleviating depressive symptoms 
and anxiety disorders in SZ subjects. The association of hypovitaminosis D with metabolic 
syndrome deserves further explorations. 
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